IDBiologics

About:

IDBiologics is a human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.

Top Investors: Launch Tennessee, Vanderbilt University, Acequia Capital (AceCap), Flying Point Industries

Description:

IDBiologics was founded in 2017 to discover and develop human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.Their innovative fully human monoclonal antibody platform enables rapid discovery and optimization of broad and potent therapeutic molecules.Using this proprietary platform, IDBiologics has accumulated unparalleled breadth in isolating antibodies for infectious diseases, with lead candidate molecules to diverse targets moving forward in development.

Total Funding Amount:

$4.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Nashville, Tennessee, United States

Founded Date:

2017-01-01

Contact Email:

info(AT)idbiologics.com

Founders:

Charles Haines, James Crowe

Number of Employees:

1-10

Last Funding Date:

2023-05-23

IPO Status:

Private

Industries: